Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M W Saif

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Cancer Chemotherapy and Pharmacology|April 9, 2013
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumorsM W Saif, C Erlichman, T Dragovich, et al.
British Journal of Cancer|February 20, 2014
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trialE Chu, D Haller, T Cartwright, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancerM W Saif, S F Leitman, G Cusack, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2015
Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trialsD G Haller, M J O'Connell, T H Cartwright, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|October 4, 2014
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expressionD Li, S Pant, D P Ryan, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Cancer Chemotherapy and Pharmacology|April 9, 2013
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumorsM W Saif, C Erlichman, T Dragovich, et al.
British Journal of Cancer|February 20, 2014
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trialE Chu, D Haller, T Cartwright, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancerM W Saif, S F Leitman, G Cusack, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2015
Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trialsD G Haller, M J O'Connell, T H Cartwright, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|October 4, 2014
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expressionD Li, S Pant, D P Ryan, et al.
Pageof 4